Zacks Research Issues Negative Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Stock analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Charles River Laboratories International in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.07 for the quarter, down from their prior estimate of $2.08. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q4 2025 earnings at $2.57 EPS, FY2025 earnings at $9.53 EPS, Q1 2026 earnings at $2.45 EPS, Q3 2026 earnings at $2.70 EPS, Q4 2026 earnings at $2.77 EPS, Q1 2027 earnings at $2.69 EPS and FY2027 earnings at $11.37 EPS.

A number of other equities analysts also recently issued reports on the stock. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. UBS Group reissued a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Finally, Mizuho dropped their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $182.00.

Remove Ads

Charles River Laboratories International Price Performance

NYSE CRL traded down $0.39 during trading hours on Tuesday, reaching $99.56. 11,602,556 shares of the stock traded hands, compared to its average volume of 858,610. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 663.71, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a 50 day simple moving average of $156.71 and a two-hundred day simple moving average of $176.86.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the previous year, the business posted $2.46 earnings per share. The company's revenue for the quarter was down 1.1% compared to the same quarter last year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter valued at $601,000. JPMorgan Chase & Co. increased its position in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares during the last quarter. State Street Corp raised its position in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares during the period. Janus Henderson Group PLC boosted its position in shares of Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock worth $9,064,000 after purchasing an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International during the third quarter worth about $966,000. Institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).